leisure time -WSS

leisure time

author：fashion 2025-09-30 16:26:58 - browse：3261

In a lab at Harvard Medical School, Professor David A. Sinclair looks into the camera from behind a row of bottles — coverage from STAT — David Sinclair in his lab at Harvard Medical School. Craig F. Walker/Globe Staff

Renowned Harvard University geneticist and longevity researcher David Sinclair recently made an astonishing assertion: Scientists had developed the first pill — well, a soft, beef-flavored chew — “proven to reverse aging” in dogs. Which miracle molecules delivered this supposed scientific breakthrough, he didn’t say. But he told his 438,000 followers on X where they could buy it: the website of Animal Bioscience, a veterinary supplement company he founded and which is headed by his brother, Nick Sinclair.

The claim in a company news release, followed by the tweet stating that the supplement was “proven to slow the effects of aging,” has sparked outrage from other scientists online, and the board of an international organization of top longevity researchers — which David Sinclair leads — will discuss the matter at its meeting this week.

Despite his enthusiasm, there is no published scientific research that has yet demonstrated the compounds in Animal Bioscience’s supplements — which have been on the market for more than a year — reverse or even slow aging in dogs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

WSS

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Flagship, Pfizer team up in deal worth up to $7 billion

FDA poised to publish guidelines for clinical trial diversity

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Flagship, Pfizer team up in deal worth up to $7 billion

FDA seeking to stop procedures at two unregulated stem cell clinics

explore

leisure time

focus

How to save PrEP access — and even expand it

ER docs worry over extreme heat as a 'mass casualty event'

Novavax promises a turnaround & Lilly roils the obesity market

Bird flu surveillance in wastewater gets boost from consortium

Apple is now the first public company to be valued at $3 trillion

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Medicare proposal to cover medical devices draws a mixed reaction

What we know about the American soldier detained in North Korea

ChatGPT in medicine: STAT answers readers' burning questions

A strong 6.5

focus

Eyeing GLP

Why you get paid to donate plasma but not blood

Manchin plays down potential 3rd

Making the case for fair compensation in clinical trials

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

As a primary care physician, here's how I hope to partner with AI

hotspot

Wikipedia

explore

focus